Cerebrospinal fluid markers for alzheimer's disease over the lifespan: Effects of age and the APOEε4 genotype

Journal of Alzheimer's Disease

Volumn 22, Issue 2, 2010, Pages 459-468

  Popp, Julius ^a   Lewczuk, Piotr ^b   Frommann, Ingo ^a   Kölsch, Heike ^a   Kornhuber, Johannes ^b   Maier, Wolfgang ^a,c   Jessen, Frank ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^c GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

Author keywords

Alzheimer's disease; amyloid ; APOE 4; cerebrospinal fluid; hyperphosphorylated tau; normal aging

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN E4; TAU PHOSPHORYLATED AT THREONINE 181; TAU PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID; COGNITIVE DEFECT; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DISEASE MARKER; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LIFESPAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN CEREBROSPINAL FLUID LEVEL; RISK FACTOR;

EID: 78650846588     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100561     Document Type: Article

References (32)

1. Sunderland T, Mirza N, Putnam KT, Linker G, Bhupali D, Durham R, Soares H, Kimmel L, Friedman D, Bergeson J, Csako G, Levy JA, Bartko JJ, Cohen RM (2004) Cerebrospinal fluid beta-amyloidl-42 and tau in control subjects at risk for Alzheimer's disease: the effect of APOE epsilon4 allele. Biol Psychiatry 56, 670-676.
2. Visser PJ, Verhey F, Knol DL, Scheltens P, Wahlund LO, Freund-Levi Y, Tsolaki M, Minthon L, Wallin AK, Hampel H, Burger K, Pirttila T, Soininen H, Rikkert MO, Verbeek MM, Spiru L, Blennow K (2009) Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study. Lancet Neurol 8, 619-627.
3. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM (2007) Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol 64, 343-349.
4. Li G, Sokal I, Quinn JF, Leverenz JB, Brodey M, Schellenberg GD, Kaye JA, Raskind MA, Zhang J, Peskind ER, Montine TJ (2007) CSF tau/Abeta42 ratio for increased risk of mild cognitive impairment: a follow-up study. Neurology 69, 631-639.
5. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L (2006) Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 5, 228-234.
6. Mattsson N, Zetterberg H, Hansson O, Andreasen N, Parnetti L, Jonsson M, Herukka SK, van der Flier WM, Blankenstein MA, Ewers M, Rich K, Kaiser E, Verbeek M, Tsolaki M, Mulugeta E, Rosen E, Aarsland D, Visser PJ, Schroder J, Marcusson J, de Leon M, Hampel H, Scheltens P, Pirttila T, Wallin A, Jonhagen ME, Minthon L, Winblad B, Blennow K (2009) CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA 302, 385-393.
7. Mahley RW, Weisgraber KH, Huang Y (2006) Apolipoprotein E4: a causative factor and therapeutic target in neuropatholo-gy, including Alzheimer's disease. Proc Natl Acad Sci U SA 103, 5644-5651.
8. Khachaturian AS, Corcoran CD, Mayer LS, Zandi PP, Breitner JC (2004) Apolipoprotein E epsilon4 count affects age at onset of Alzheimer disease, but not lifetime susceptibility: The Cache County Study. Arch Gen Psychiatry 61, 518-524.
9. Raber J, Huang Y, Ashford JW (2004) ApoE genotype accounts for the vast majority of AD risk and AD pathology. Neurobiol Aging 25, 641-650.
10. Polvikoski T, Sulkava R, Haltia M, Kainulainen K, Vuorio A, Verkkoniemi A, Niinisto L, Halonen P, Kontula K (1995) Apolipoprotein E, dementia, and cortical deposition of beta-amyloid protein. N Engl J Med 333, 1242-1247.
11. Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttila T (2009) Cerebrospinal fluid -amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 66, 382-389.
12. Engelborghs S, Sleegers K, Cras P, Brouwers N, Serneels S, De Leenheir E, Martin JJ, Vanmechelen E, Van Broeck-hoven C, De Deyn PP (2007) No association of CSF biomarkers with APOEepsilon4, plaque and tangle burden in definite Alzheimer's disease. Brain 130, 2320-2326.
13. Tapiola T, Pirttila T, Mehta PD, Alafuzoff I, Lehtovirta M, Soininen H (2000) Relationship between apoE genotype and CSF beta-amyloid (1-42) and tau in patients with probable and definite Alzheimer's disease. Neurobiol Aging 21, 735-740.
14. Prince JA, Zetterberg H, Andreasen N, Marcusson J, Blennow K (2004) APOE epsilon4 allele is associated with reduced cerebrospinal fluid levels of AbetaNeurology 62, 2116-2118.
15. Kester MI, Blankenstein MA, Bouwman FH, van Elk EJ, Scheltens P, van der Flier WM (2009) CSF biomarkers in Alzheimer's disease and controls: associations with APOE genotype are modified by age. J Alzheimers Dis 16, 601-607.
16. Glodzik-Sobanska L, Pirraglia E, Brys M, de Santi S, Mosconi L, Rich KE, Switalski R, Saint Louis L, Sadowski MJ, Mar-tiniuk F, Mehta P, Pratico D, Zinkowski RP, Blennow K, de Leon MJ (2009) The effects of normal aging and ApoE genotype on the levels of CSF biomarkers for Alzheimer's disease. Neurobiol Aging 30, 672-681.
17. Peskind ER, Li G, Shofer J, Quinn JF, Kaye JA, Clark CM, Farlow MR, DeCarli C, Raskind MA, Schellenberg GD, Lee VM, Galasko DR (2006) Age and apolipoprotein E*4 allele effects on cerebrospinal fluid beta-amyloid 42 in adults with normal cognition. Arch Neurol 63, 936-939.
18. Folstein MF, Folstein SE, McHugh PR (1975) "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. JPsychiatr Res 12, 189-198.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM (1984) Clinical diagnosis ofAlzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944.
20. Lewczuk P, Kamrowski-Kruck H, Peters O, Heuser I, Jessen F, Popp J, Burger K, Hampel H, Frolich L, Wolf S, Prinz B, Jahn H, Luckhaus C, Perneczky R, Hull M, Schroder J, Kessler H, Pantel J, Gertz HJ, Klafki HW, Kolsch H, Reulbach U, Esselmann H, Maler JM, Bibl M, Kornhuber J, Wiltfang J (2008) Soluble amyloid precursor proteins in the cerebrospinal fluid as novel potential biomarkers of Alzheimer's disease: a multicenter study. Mol Psychiatry 15, 138-145.
21. Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS (2006) Neuropathology of older persons without cognitive impairment from two community-based studies. Neurology 66, 1837-1844.
22. Price JL, McKeel DW, Jr., Buckles VD, Roe CM, Xiong C, Grundman M, Hansen LA, Petersen RC, Parisi JE, Dickson DW, Smith CD, Davis DG, Schmitt FA, Markesbery WR, Kaye J, Kurlan R, Hulette C, Kurland BF, Higdon R, Kukull W, Morris JC (2009) Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease. Neurobiol Aging 30, 1026-1036.
23. Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haa-pasalo H, Karhunen PJ (2009) Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol 65, 650-657.
24. Sjogren M, Vanderstichele H, Agren H, Zachrisson O, Eds-bagge M, Wikkelso C, Skoog I, Wallin A, Wahlund LO, Mar-cusson J, Nagga K, Andreasen N, Davidsson P, Vanmechelen, Blennow K (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21-93 years of age: establishment of reference values. Clin Chem 47, 1776-1781.
25. Shoji M, Kanai M, Matsubara E, Tomidokoro Y, Shizuka M, Ikeda Y, Ikeda M, Harigaya Y, Okamoto K, Hirai S (2001) The levels ofcerebrospinal fluid Abeta40 and Abeta42(43) are regulated age-dependently. Neurobiol Aging 22, 209-215.
26. Jessen F, Wiese B, Bachmann C, Eifflaender-Gorfer S, Haller, Kolsch H, Luck T, Mosch E, Kaduszkiewicz H, Wagner M, Wollny A, Zimmermann T, Pentzek M, Riedel-Heller SG, Weyerer S, van den Bussche H, Maier W, Bickel H (2010) Prediction of dementia by subjective memory impairment -effects of severity and temporal association with cognitive impairment. Arch Gen Psychiatry 67, 414-422.
27. Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM (2002) Human and murine ApoE markedly alters A beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis 9, 305-318.
28. Bales KR, Liu F, Wu S, Lin S, Koger D, DeLong C, Hansen JC, Sullivan PM, Paul SM (2009) Human APOE isoform-dependent effects on brain beta-amyloid levels in PDAPP transgenic mice. J Neurosci 29, 6771-6779.
29. Bennett DA, Wilson RS, Schneider JA, Evans DA, Aggarwal NT, Arnold SE, Cochran EJ, Berry-Kravis E, Bienias JL (2003) Apolipoprotein E epsilon4 allele, AD pathology, and the clinical expression of Alzheimer's disease. Neurology 60, 246-252.
30. Drzezga A, Grimmer T, Henriksen G, Muhlau M, Perneczky R, Miederer I, Praus C, Sorg C, Wohlschlager A, Riemenschneider M, Wester HJ, Foerstl H, Schwaiger M, Kurz A (2009) Effect of APOE genotype on amyloid plaque load and gray matter volume in Alzheimer disease. Neurology 72, 1487-1494.
31. Reiman EM, Chen K, Liu X, Bandy D, Yu M, Lee W, Ayutyanont N, Keppler J, Reeder SA, Langbaum JB, Alexander GE, Klunk WE, Mathis CA, Price JC, Aizenstein HJ, DeKosky ST, Caselli RJ (2009) Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA 106, 6820-6825.
32. Hulstaert F, Blennow K, Ivanoiu A, Schoonderwaldt HC, Riemenschneider M, De Deyn PP, Bancher C, Cras P, Wiltfang J, Mehta PD, Iqbal K, Pottel H, Vanmechelen E, Van-derstichele H (1999) Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF. Neurology 52, 1555-1562.